Home AstraZeneca Shares Gain Ground on Results from Covid-19 Vaccine Progress
Stock Market Analysis & News

AstraZeneca Shares Gain Ground on Results from Covid-19 Vaccine Progress

Galina Mikova
Fact Checked
Fact Checked
Everything you read on our site is provided by expert writers who have many years of experience in the financial markets and have written for other top financial publications. Every piece of information here is fact-checked.
Please note that we are not authorised to provide any investment advice. The information on this page should be construed for information purposes only. We may earn commissions from the products mentioned on this site.
AstraZeneca vaccine trial

In Wednesday’s trading session, shares of AstraZaneca were up 5% on the news a medical journal will publish positive data from the company’s early-stage human trial data on its coronavirus vaccine on July 20. The results from early tests of the vaccine will be published by the medical journal The Lancet, possibly on Thursday, according to a report on British television channel ITV’s website.

Since mid-March AstraZaneca Shares have jumped 53% as the British pharmaceutical giant struck a deal to supply Europe with a coronavirus vaccine and joined the list of companies engaged in the development of a potential coronavirus vaccine under President Trump’s “Warp Speed” project. Under the latter, the company will have access to unlimited resources of federal funding alongside Merck, Pfizer, Johnson & Johnson and Moderna in an attempt to fast-track a Coronavirus vaccine by the end of the year.

AstraZeneca shares

Preliminary data from the vaccine trial is showing the kind of antibody and T-cell (killer cell) response that the researchers would hope to see, the report said, citing sources.

“We expect this paper, which is undergoing final editing and preparation, to be published on Monday, July 20, for immediate release,” a spokeswoman for the journal told Reuters.

Last month, AstraZeneca confirmed it was boosting its manufacturing capacity of a potential COVID-19 vaccine to 2 billion doses ahead of the results of clinical trials later this summer.

The company also reached an agreement with Europe’s Inclusive Vaccines Alliance to supply European nations with as many as 400 million doses of a covid-19 vaccine – if the vaccine under consideration proves safe and effective.

AstraZeneca Analyst View


If AstraZeneca’s jab proves successful, the drugmaker expects to distribute a billion doses globally by the end of 2020. It has already inked deals to produce 400million for the US and 100million for the UK with British ministers having agreed to pay for the doses ‘as early as possible’. Hopes are high that those will be ready for September if proven effective.

About 160 coronavirus vaccines are in various stages of development around the world, according to the World Health Organization.

AstraZeneca’s Oxford vaccine has already begun final-stage testing. The company has said it may begin delivering doses of the vaccine as early as September.

Stock Forecast


JPMorgan set a GBX 9,500 target price on AstraZeneca and has a ‘Buy’ rating on the biopharmaceutical company’s stock. Several other equity research firms have also updated their outlook AstraZeneca.

Promising results from its COVID vaccine trial as well as secured government contracts are fuelling investor interest in AstraZeneca. Overall, the stock scores a Strong Buy consensus from the analyst community, putting it among the best shares to buy right now.


Question & Answers (0)

Have a question? Our panel of experts will answer your queries. Post your Question

Leave a Reply

Write a Review

Your email address will not be published. Required fields are marked *

Galina Mikova

Galina Mikova

Galina is a Hubspot-certified Technical Writer with over 10 years of experience in working with Fortune 500, private investment, banking, FOREX and niche tech companies as well as crypto and blockchain startups. She has a solid background in FinTech and blockchain technology. As well as BuyShares, Galina has also written for LearnBonds, 100 Forex Brokers, AMMEX, and ICO Bench.